News Article | February 28, 2017
With an upcoming publication in the Worldwide Leaders in Healthcare, Nyree L. Parker, RN/Clinical Nurse Specialist, Dip. Health Science, BN, Graduate Certificate of Health Education, Graduate Certificate Health Promotion, Graduate Diploma Critical Care/Emergency, MN, Master Degree in Disaster Health, joins the prestigious ranks of the International Nurses Association. She is a Registered Nurse with twenty-four years of experience in her field and extensive expertise in all facets of nursing, including emergency care and Disaster Health. Nyree is currently serving patients as Clinical Nurse Specialist in the Emergency Department and Emergency Management and BCP Consultant in the Facilities Management Department at Peninsula Health in Victoria, Australia. This involves policy and procedure/plan writings for i.e. mass casualties incidents, CBR decontamination processes, pandemics, heatwaves, bushfires and severe weather impacting on the public hospital organisation. Furthermore, she works as Assistance in Care Emergency Volunteer Coordinator in the Emergency Departments at Peninsula Health Frankston Hospital in Frankston, Victoria, Australia. Nyree acquired her graduate diploma in applied sciences in 1991 at Monash University, where she also received her bachelor degree of nursing in 1992. She also obtained a diploma of critical care nursing majoring in Emergency care (1997), a master degree of nursing (2001), and a Master Degree in emergency Disaster Health (2013) at Monash University. In 1998, Nyree earned a postgraduate certificate in health promotion from Deakin University. She is a Clinical Nurse Specialist and was a Trauma Nursing Core Course Instructor as well as a member of the Australian College of Emergency Nursing, the Victoria Hospital Management Forum, the Royal College of Nursing Australia, the Australian Nurses Federation, and an active member of the Nursing Section of the World Association of Disaster Emergency Medicine. Furthermore, she was honoured with the Dux of Group Award in 2009 and was a volunteers with St. John’s Ambulance. Nyree credits her success to being a third generation nurse in her family. She also has acted as a Clinical Instructor of Emergency Management and Critical Care at Monash University. Nyree is aiming to commence her PhD in Disaster Health looking at topics of climate change implications on emergency nurses and the role of an Emergency Management Consultant in the hospital environment. In her spare time, Nyree enjoys reading the Great Hospital Emergency Disaster Relief Journal and the Emergency Medicine News Journal. She also dedicates to dog walking and antique shopping and driving her 1948 Morris car! Learn more about Nyree here: http://inanurse.org/network/index.php?do=/4125803/info/ and read her upcoming publication in the Worldwide Leaders in Healthcare.
News Article | February 21, 2017
Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering. This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed. The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature. Benefits of this report: - Up-to-date one-stop information on therapeutic drug monitoring - Description of 27 companies involved with their collaborations in this area - Market analysis 2016-2026/ - Market values in major regions - Strategies for developing markets for therapeutic drug monitoring - A selected bibliography of 190 publications - Text is supplemented by 18 tables and 6 figures Who should read this report? - Biotechnology companies developing assays and equipment for drug monitoring - Reference laboratories providing drug monitoring services - Pharmaceutical companies interested in companion tests for monitoring their drugs - Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine Key Topics Covered: Executive Summary 1. Introduction Definitions Historical Landmarks in the development of TDM Pharmacology relevant to TDM Pharmacokinetics Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacoproteomics Drug receptors Protein binding Therapeutic range of a drug Variables that affect TDM Indications for TDM Multidisciplinary nature of TDM 2. Technologies for TDM Introduction Sample preparation Proteomic technologies Mass spectrometry Liquid chromatography MS Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Combining capillary electrophoresis with MS Gas-liquid chromatography Tissue imaging mass spectrometry New trends in sample preparation Pressure Cycling Technology Desorption electrospray ionization imaging High Performance Liquid Chromatography (HPLC) Ultra performance LC TDM using dry blood spots Analysis of dried blood spots for drugs using DESI Quantitative analysis of drugs in dried blood spot by paper spray MS Immunoassays Enzyme-linked immunosorbent assay Cloned Enzyme Donor Immunoassay Enzyme Multiplied Immunoassay Technique Fluorescence Polarization Immunoassay Particle Enhanced Turbidimetric Inhibition Immunoassay Radioimmunometric assays Biosensors Nanosensors Biochips & Microarrays Introduction Microchip capillary electrophoresis Phototransistor biochip biosensor Microchip-based fluorescence polarization immunoassay for TDM Cellular microarrays Microfluidics for TDM Lab-on-a-chip Micronics' microfluidic technology Rheonix CARD technology Nano-interface in a microfluidic chip Levitation of nanofluidic drops with physical forces Nanoarrays Nanobiotechology NanoDx Biomarkers Applications of biomarkers in drug safety studies Genomic technologies for toxicology biomarkers Proteomic technologies for toxicology biomarkers Metabonomic technologies for toxicology biomarkers Integration of genomic and metabonomic data to develop toxicity biomarkers Toxicology studies based on biomarkers Biomarkers of hepatotoxicity Biomarkers of nephrotoxicity Cardiotoxicity Neurotoxicity Biomarkers in clinical trials Molecular diagnostics 3. Drug Monitoring Instruments Introduction Description of important instruments AB SCIEX instruments AB SCIEX LC/MS/MS Abbott instruments ARCHITECT c16000 ARCHITECT c4000 ARCHITECT c8000 ARCHITECT ci16200 Integrated System ARCHITECT ci4100 Integrated System ARCHITECT ci8200 integrated with the ARCHITECT i2000SR ARCHITECT i1000SR ARCHITECT i4000SR AxSYM Agilent's 6400 Series Triple Quadrupole LC/MS Alfa Wassermann's ACE Alera AMS Diagnostics' LIASYS Awareness Technology's STAT FAX 4500 Beckman Coulter instruments Beckman Coulter Unicel Series AU5800 automated chemistry systems AU480 Binding Site ESP600 bioMerieux Mini Vidas Carolina BioLis 24i Chromsystems' HPLC instruments Grifols Triturus ABX Pentra 400 Medica EasyRA Nova Biomedical Critical Care Xpress Ortho Clinical Diagnostics' VITROS® family of systems Immunodiagnostic systems Randox intruments Randox RX Imola Roche instruments Cobas® 8000 COBAS INTEGRA® Systems Siemens instruments ADVIA 1200 ADVIA Centaur XP immunoassay system EMIT® II Plus Syva® Viva® Drug Testing Systems Dimension® Xpand® Plus Integrated Chemistry System Thermo Scientific instruments Indiko Tosoh AIA-Series 4. Applications of TDM Introduction Pharmaceutical research and drug development Clinical trials Computerized clinical decision support systems for TDM and dosing Medication-related interferences with measurements of catecholamines Polymorphisms of genes affecting drug metabolism TDM for drug safety TDM in special groups The aged Children Pregnancy TDM of prophylactic therapy Monitoring of vitamin D levels Monitoring of RBC folic acid levels during pregancy Personalized medicine Role of TDM in personalized medicine Applications according to various conditions Anesthesia and critical care Optimizing antimicrobial dosing for critically ill patients TDM monitoring of thiopental continuous infusion in critical care Role of TDM in critical care cardiac patients. Cancer Epilepsy Personalized approach to use of AEDs Infections Virus infections Fungal infections Pain management Role of TDM in pain management Monitoring of analgesic drugs in urine samples AEDs as analgesics Triptans for migraine Psychiatric disorders Guidelines for use of TDM in psychiatric patients TDM of psychotropic drugs Transplantation TDM of Tacrolismus in transplantation TDM of cyclosporine A in transplantation Monitoring of immunosuppression with mycophenolate mofetil Emergency toxicology Future prospects of TDM 5. Drugs Requiring Monitoring Introduction Antiepileptics Carbamazepine TDM of carbamazepine Gabapentin Lacosamide Lamotrigine TDM of lamotrigine Levetiracetam TDM of levetiracetam Phenobarbital TDM of phenobarbital Phenytoin TDM of phenytoin Primidone TDM of primidone Topiramate TDM of topiramate Valproic acid TDM of valproic acid TDM of multiple antiepileptic drugs in plasma/serum Antimicrobials Antibiotics Amikacin Anti-tuberculosis drugs Chloramphenicol Gentamicin Tobramycin Vancomycin Norvancomycin Antiviral agents Anti-HIV drugs Antifungal agents Voriconazole Antidepressants TDM of selective serotonin reuptake inhibitors Antipsychotics Aripiprazole Quetiapine TDM of risperidone TDM of AEDs in psychiatric disorders TDM of multiple drugs in psychiatry Bronchodilators Theophylline Cardiovascular drugs Antiarrhythmic drugs Anticoagulants Dabigatran Antihypertensive drugs ß-blockers Cardiotonic drugs Digoxin TDM of statins for hypercholesterolemia Chemotherapy for cancer TDM of 5-FU TDM of Methotrexate TDM of imitanib Drugs used for treatment of Alzheimer disease Donepezil Galantamine Memantine Drugs used for treatment of Parkinson disease Monitoring of levodopa and carbidopa therapy Catechol-O-methyltransferase inhibitors Drugs for treatment of attention-deficit hyperactivity disorder Atomoxetine Methylphenidate Hypnotic-sedative drugs Benzodiazepines Propofol Immunosuppressive drugs TDM of mycophenolic acid for the treatment of lupus nephritis Steroids Prednisone Miscellaneous drugs Azathioprine Sildenafil 6. Monitoring of Biological Therapies Introduction Cell therapy In vivo tracking of cells Molecular imaging for tracking cells MRI technologies for tracking cells Superparamagnetic iron oxide nanoparticles as MRI contrast agents Visualization of gene expression in vivo by MRI Gene therapy Application of molecular diagnostic methods in gene therapy Use of PCR to study biodistribution of gene therapy vector PCR for verification of the transcription of DNA In situ PCR for direct quantification of gene transfer into cells Detection of retroviruses by reverse transcriptase (RT)-PCR Confirmation of viral vector integration Monitoring of gene expression Monitoring of gene expression by green fluorescent protein Monitoring in vivo gene expression by molecular imaging Monoclonal antibodies Natalizumab 7. Monitoring of Drug Abuse Introduction Tests used for detection of drug abuse Forensic applications of detection of illicit drugs in fingerprints by MALDI MS MS for doping control Randox assays for DoA Drugs of Abuse Array V Urine drug testing TDM of drugs for treatment of substance abuse-related disorders Drug testing to monitor treatment of drug abuse Minimum requirement for drug testing in patients Analgesic abuse ?-blockers as doping agents Detection of ß-blockers in urine Chronic alcohol abuse Cocaine CEDIA for cocaine in human serum Detection of cocaine molecules by nanoparticle-labeled aptasensors Infrared spectroscopy for detection of cocaine in saliva Marijuana Use of marijuana and synthetic cannabinoids Detection of cannabinoids ELISA for detection of synthetic cannabinoids Drug abuse for performance enhancement in sports Historical aspects of drug abuse in sports Drugs used by athletes for performance enhancement Techniques used for detection of drug abuse by athletes Mass spectrometry for detection of peptide hormones miRNAs for the detection of erythropoiesis-stimulating agents Detection of anabolic steroids Body fluids and tissues used for detection of drug abuse in sports Urine drug testing Spray (sweat) drug test kits Hair drug testing Gene doping in sports Gene transfer methods used for enhancing physical performance Misuse of cell therapy in sport Challenges of detecting genetic manipulations in athletes Drug abuse testing in race horses Limitations and future prospects Role of pharmaceutical industry in anti-doping testing 8. Markets for TDM Introduction Methods for market estimation and future forecasts Markets for TDM tests Markets for TDM and DoA testing equipment Geographical distribution of markets for TDM tests Drivers for growth of TDM markets Markets for DoA testing Unmet needs in TDM Cost-benefit studies Simplifying assays and reducing time and cost Strategies for developing markets Physician education Supporting research on TDM Biomarker patents for drug monitoring 9. Companies Profiles of companies Collaborations 10. References For more information about this report visit http://www.researchandmarkets.com/research/g4tq2x/therapeutic_drug
News Article | February 22, 2017
NEW YORK, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dr. Sharon Metcalfe, Interim Director of Nursing at Western Carolina University, has been selected to join the Education Board at the American Health Council. She will be sharing her knowledge and expertise on Nursing Education and Clinical / Didactic Testing. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0ead4c6b-51d4-40e9-90ea-cb328bbfeb1a With over a decade of experience in the field of Nursing Education, Dr. Metcalfe offers valuable insight in her role as the Interim Director of Nursing at Western Carolina University. Located in Cullowhee, North Carolina, Western Carolina University is a public regional institution of higher education that is committed to offering quality education at an affordable rate. Ranked as one of the top fifteen public regional institutions in the South, WCU give prospective students an opportunity to choose from more than a hundred and fifteen majors and concentrations ranging from Biology, Computer Information Systems, Spanish, Business Administration and much more. As the Interim Director of Nursing at Western Carolina University, Dr. Metcalfe’s day-to-day responsibilities include oversight of programs and forty facilities, management of scholarships, the university budget, and community groups. Prior to her role as the Interim Director, Dr. Metcalfe gained leadership experience as the Dean of Nursing for at Lees-McRae College and Mayland Community College. In the clinical setting, Dr. Metcalfe has served as the Director of Pediatrics (Denver, Colorado Children's Hospital), Director of Neonatal Services at Rose Medical Center (Denver, Colorado), and Nursing Administrator of Pediatrics, Critical Care, Intensive Care, and Neonatal Intensive Care at Wake Forest Medical Center-Baptist Hospital (Winston-Salem, North Carolina). In 1997, Dr. Metcalfe earned her Doctorate of Education in Adult and Community College Education from the North Carolina State University. She went on to complete a Bachelor of Science in Nursing degree and receive certification as a Registered Nurse from the University of Colorado. Dr. Metcalfe maintains affiliations with the North Carolina Nurses Association and Sigma Theta Tao. She serves on the Board of Directors for the Mountain Area Health Education Minority and Underrepresented Students Council, and the Board of Directors for the Social Services division of Asheville, North Carolina. Dr. Metcalfe’s desire to pursue Nursing Education developed through a natural progression. Looking back, she attributes her success to her supportive husband Lee and her loving son Trevor. Due to her commitment and dedication to the field of Nursing Education, Dr. Metcalfe has been awarded the 2016 Health Science College Award, 2006 100 Best Nurses Award, and 2005 Native American Teacher of the Year. Among her many accomplishments, Dr. Metcalfe has published three significant articles on mentoring, social determinants and educational barriers for diverse students, and the nature of cultural competency. In her free time, she enjoys traveling to Europe. As a certified Parent Child Interventionist, Dr. Metcalfe volunteers her time being a high risk parenting educator for the Department of Social Work conducting seminars for foster parents that struggle with difficult children during the fall of each year. Considering her future, Dr. Metcalfe hopes for continual growth in research, and education by teaching a RN to BSN program.
News Article | February 23, 2017
YONKERS, N.Y.--(BUSINESS WIRE)--In a promising development for pet cancer patients in the Northeast, Animal Specialty Center (ASC) introduced its new TrueBeam™ Radiotherapy system to leading veterinary professionals with a formal ribbon cutting ceremony. The ribbon cutting for the TrueBeam system was part of a continuing education seminar that included a presentation entitled, “Combining Surgery and Radiation” by ASC’s Kendra Hearon, DVM, DACVS, Fellow in Surgical Oncology. “We are very excited to introduce this new technology to veterinary professionals because is it a real game-changer that will enable us to treat even the most challenging cases with unprecedented speed and pinpoint precision,” said Kari Rosen, DVM, DACVR RO at ASC. “With a broad spectrum of new capabilities, TrueBeam breaks the mold in just about every dimension, making it possible for us to offer faster, more targeted treatments to tumors even as they move and change over time.” “VCA is on the forefront of cancer treatment using the most sophisticated technology available to fight cancer,” said Karen Oberthaler, VMD, DACVIM Medical Oncology. “It’s vitally important for our profession to learn about new modalities and how they can be combined for maximum effectiveness, especially since there is very little in veterinary literature about this, despite its increasing frequency. This is a breakthrough that lets us bring a wider spectrum of advanced radiotherapy treatment options to many more patients.” More than 60 veterinarians and veterinary technicians were in attendance for the seminar, which was followed by a lively Q&A session. Among those participating in the ribbon cutting ceremony were Drs. Rosen, Hearon and Oberthaler from ASC, along with 40 industry colleagues. Located in Yonkers, New York, Animal Specialty Center is a full-service hospital staffed with leading board certified veterinary specialists, emergency doctors and a highly skilled support staff. The center offers 24/7 emergency care; critical care; internal medicine; neurology; medical oncology; radiation oncology; dentistry; cardiology; rehabilitation; and surgery and acupuncture. Our facility serves pet owners and their pets from Westchester and Rockland Counties, Connecticut, Manhattan and the Bronx. Clients from around the world have traveled to the hospital for consultations with highly skilled veterinary specialists, as well as our advanced, cutting edge diagnostic equipment and therapeutic procedures. The center provides an unparalleled level of comprehensive, specialized care with a team approach working closely with pet owners and family veterinarians from diagnosis through after care. VCA Animal Hospitals operates more than 650 small animal veterinary hospitals in the U.S. and Canada. The hospitals are staffed by more than 4,500 fully qualified, dedicated and compassionate veterinarians to give pets the very best in medical care, of which over 500 are board-certified specialists who are experts in areas such as Oncology, Cardiology, Emergency & Critical Care, and Surgery for animals. VCA Animal Hospitals provides a full range of general practice services to keep pets well and specialized treatments when pets are ill. For more information, please visit www.VCAhospitals.com or follow on Twitter @vcapethealth.
News Article | February 21, 2017
Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials BOSTON, MA and MORRISTOWN, NJ--(Marketwired - February 21, 2017) - BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin's (pGSN) role in immune function announced that it has expanded its clinical advisory board to include John Kellum, M.D. -- noted critical care physician and acute kidney injury expert at the University of Pittsburgh Medical Center. John Kellum, M.D. is a clinician scientist whose research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, and renal replacement therapy), sepsis and multi-organ failure (including blood purification), and clinical epidemiology. His research has received continuous funding from the National Institutes of Health since 2001, and he has active funding from multiple different NIH Institutes. Dr. Kellum has authored more than 300 publications and has also edited several major textbooks including Critical Care Nephrology and Stewart's Textbook of Acid-Base. Steven Opal, M.D. Professor of Medicine, Brown University School of Medicine; Chief, Infectious Disease Division, Memorial Hospital of RI Atul Malhotra, M.D. Division Chief, Pulmonary and Critical Care Medicine, Kenneth M. Moser Professor, Department of Medicine University of California-San Diego. Vice President, American Thoracic Society (2015-16 President) Acute Kidney Injury (AKI) is known to be a common occurrence in Severe Community-Acquired Pneumonia patients (SCAP). Data from a recent study of 1,800 community-acquired pneumonia patients (GenIMS Study) indicated that approximately one-third of SCAP patients were diagnosed with AKI. Patients with AKI exhibited longer stay in the hospital and had approximately ten times the risk of death at discharge (11% versus 1.3%). Plasma Gelsolin Plasma gelsolin (pGSN) becomes depleted in a wide range of inflammatory conditions, and critically low levels associate with significant morbidity and mortality in animals and humans. Data from many independent laboratories documenting that plasma gelsolin administration produces striking recoveries from lethal infections in experimental animals -- in the absence of antibiotic therapy -- strongly supports the rationale for pGSN repletion therapy. Also in support of this approach is the fact that no adverse effects have emerged from extensive preclinical toxicity studies with plasma gelsolin nor from the administration of recombinant gelsolin by different routes to healthy and diseased humans in three separate clinical studies. Based on recent breakthrough findings by Dr. Lester Kobzik at the TH Chan Harvard School of Public Health, plasma gelsolin replacement therapy markedly decreased mortality of murine pneumonia due to its stimulation of macrophages' ability to ingest and kill bacteria. Based on prior studies demonstrating rhu-pGSN's protective effect in models of infection and organ failure, it is expected that this therapeutic will reduce the incidence of acute kidney injury and its longterm consequences. The company is planning to conduct studies to treat severe community-acquired pneumonia, a leading cause of death in the US and around the world despite antibiotics and improved levels of care. Susan Levinson, Ph.D., Chief Executive Officer of BioAegis stated, "We are delighted to add John Kellum to our prestigious clinical advisory board as we advance our development efforts towards our next clinical study." John Kellum commented, "The incidence of AKI in severe pneumonia is well-known, but the long-term adverse effects are often underappreciated. A therapeutic agent such as plasma gelsolin may have the potential to reduce acute kidney injury in these patients." About BioAegis Therapeutics Founded by a group of highly experienced pharmaceutical and business executives, BioAegis' mission is to harness the body's innate immune system to address adverse outcomes in diseases driven by inflammation and infection. This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward- looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made. Image Available: http://www.marketwire.com/library/MwGo/2017/2/21/11G130819/Images/Kellum-7b172312af54b2bbaf806fb1170e815f.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/2/21/11G130819/Images/opal-e781fc12c841954da7ae7091ec80947d.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/2/21/11G130819/Images/smalleratul-22c4d7ef766cbc0f858147a4442e2f42.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/2/21/11G130819/Images/thompson-f7ddd39b3c3c930e8ee9e15dea473d19.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/2/21/11G130819/Images/vincent-d5210971e55a8524803fa4c69bd36fe1.jpg
News Article | February 15, 2017
IRVINE, Calif.--(BUSINESS WIRE)--Recently published editions of two leading critical care nursing textbooks now include discussions about automated pupillometry, based on comprehensive reviews of state-of-the-art information about critical care procedures. Pupillary examination is a critical component of neurological assessment. Abnormalities in pupillary response and pupil asymmetry are often associated with neurologic deterioration and correlate with poor neurological outcome. Manual pupillary assessment is subject to inaccuracies and inconsistencies, and is characterized by high inter-examiner variability. The NeurOptics NPi-200 Pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing more accurate, reliable, and objective pupil size and reactivity measurement for this vital component of neurological examinations. NeurOptics will exhibit its NPi-200 Pupillometer at the International Stroke Conference, Feb. 22-24, 2017, in Houston (booth No. 714). The American Association of Critical-Care Nurses (AACN) Procedure Manual for High Acuity, Progressive and Critical Care, 7th Edition, and the American Association of Neuroscience Nurses (AANN) Core Curriculum for Neuroscience Nursing, 6th Edition, now include sections illustrating how use of a pupillometer removes subjectivity and allows pupillary reactivity to be trended in a consistent, objective, and quantifiable way. The AACN Procedure Manual, which was extensively reviewed by more than 100 experts in critical care nursing, is the authoritative reference for procedures performed in critical care settings, and the AANN curriculum is a comprehensive resource for practicing neuroscience nurses. “We are excited that the foremost authorities on critical care and neuroscience nursing have recognized the importance of automated pupillometry in the assessment of patients with neurologic injuries,” said William Worthen, President and CEO of NeurOptics. “The NeurOptics Pupillometer benefits clinicians and patients by measuring pupil reactivity numerically so that now, for the first time, both pupil size and reactivity can be accurately trended for changes—just like other vital signs.” Traditionally, pupil measurements have been performed in a subjective manner by clinicians using a penlight to manually evaluate pupil size and reactivity—a method prone to significant inaccuracies and inconsistencies. In contrast, the NeurOptics NPi-200 Pupillometer is a portable, hand-held, infrared device that provides a reliable and objective measurement of pupillary size, symmetry, and reactivity. The numeric scale of the Neurological Pupil index (NPi®) allows a much more rigorous interpretation and classification of pupil reactivity. With the NPi-200 Pupillometer System, patient data can be uploaded into a hospital’s electronic medical record (EMR) system, saving valuable nursing time and eliminating potential charting errors. NeurOptics is the leader in the science of pupillometry. Driven by a passion to help clinicians improve patient outcomes, NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, ophthalmology, and research. The NeurOptics NPi-200 Pupillometer has been adopted in over 400 critical care units in the United States. Headquartered in Irvine, Calif., NeurOptics is represented in more than 20 countries worldwide. For more information, visit www.NeurOptics.com. Follow NeurOptics on Facebook and Twitter @NeurOpticsInc. Note to editors: A fact sheet about the NeurOptics Pupillometer is available here.
News Article | February 15, 2017
SACRAMENTO, Calif.--(BUSINESS WIRE)--VCA Animal Hospitals announced that select VCA hospitals in northern California are offering free boarding assistance for small animals, including dogs, cats, birds and pocket pets, for families who are being displaced by the evacuation orders due to the damaged Oroville Dam emergency spillway which could potentially flood Oroville and other towns in Yuba, Sutter and Butte counties. “Our thoughts are with the many thousands of families who are being impacted by these mass evacuations,” said Art Antin, Chief Operating Officer of VCA Animal Hospitals. “We are extending free boarding for as many pets as we can accommodate so families can be assured their animals are safe and be able to focus on their priorities during this critical time.” Boarding assistance at participating northern California area VCA hospitals is based on space availability. Pets should be current on vaccinations, but in case they are not, VCA veterinarians will update vaccinations free of charge. VCA will also offer a free health assessment exam for pets that have been evacuated or displaced due to the Oroville Dam evacuation orders. To check availability for boarding assistance, visit www.vcahospitals.com/main/directory or call 1-800-VCAPETS. VCA Animal Hospitals operates more than 650 small animal veterinary hospitals in the U.S. and Canada. The hospitals are staffed by more than 4,500 fully qualified, dedicated and compassionate veterinarians to give pets the very best in medical care, of which over 500 are board-certified specialists who are experts in areas such as Oncology, Cardiology, Emergency & Critical Care, and Surgery for animals. VCA Animal Hospitals provides a full range of general practice services to keep pets well and specialized treatments when pets are ill. For more information, please visit www.VCAhospitals.com or follow on Twitter @vcapethealth.
News Article | February 15, 2017
The International Nurses Association is pleased to welcome Debra White, RN, to their prestigious organization with her upcoming publication in the Worldwide Leaders in Healthcare. Debra White is a Registered Nurse with 28 years of experience in her field and an extensive expertise in all facets of nursing, especially critical care. Debra is currently serving patients as a Specialty Field Nurse, Critical Care Nurse, and Paramedic Examiner. She is also a Clinical Lead/Faculty in Health and Wellness at Georgian College in Barrie, Ontario. Debra White attended McMaster University, graduating with her Nursing Degree. Since graduating, Debra has completed numerous advanced training courses. She is certified in Advanced Cardiac Life Support, Pediatric Advanced Life Support, Chemotherapy/Biotherapy, Cardiac Medicine, Intensive Care, EKG, Neonatal Resuscitation Program, and Telemetry. Furthermore, Debra is a Certified Ambulatory Perianesthesia Nurse, Certified Critical Care Nurse, Certified Emergency Nurse, Certified Nurse, Educator, Certified Phlebotomy Technician, Certified Registered Nurse Intravenous, Certified Critical Care Transportation Nurse, and a Certified Vascular Nurse. Throughout her career, Debra has worked in many areas of the nursing field. She maintains professional memberships with the Registered Nurses of Ontario, the Gerontological Nursing Association of Ontario, the Canadian Nurses Association, the Senior Health Research Transfer Networks, the Canadian and Ontario Networks for the Prevention of Elderly Abuse, and the Canadian Association of Health Sciences and Policy Research. She attributes her success to her passion for nursing and for helping others, and when she is not working, Debra enjoys running, skiing and driving ATVs, and is also involved in a number of philanthropic causes. Learn more about Debra White here: http://inanurse.org/network/index.php?do=/4133937/info/ and be sure to read her upcoming publication in Worldwide Leaders in Healthcare.
News Article | February 25, 2017
Receive press releases from Air EMS, Inc.: By Email Air EMS, Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), proudly announced today that the company has been awarded condition accreditation through the Commission on Accreditation of Medical Transport Systems (CAMTS) for its fixed-wing air ambulance and medical escort services. Tulsa, OK, February 25, 2017 --( “Air EMS is honored to be accredited through CAMTS for medical escort and fixed-wing air ambulance transport at the Emergency Critical Care level. I could not be more proud of our team,” stated Air EMS President and Program Director, Angela Hall. Air EMS, in conjunction with its aviation operators, Jet Logistics and Flight Concepts, provide fixed-wing air ambulance transport to clients within the continental U.S. and worldwide utilizing a diverse fleet of aircraft including one of the industries only Hawker 800A’s for ultra long haul transports, in addition to Learjet 35/36 and others. CAMTS is an association of 21 non-profit organizations dedicated to improving the safety and quality of medical transport services through voluntary accreditation. To become accredited, a transport program must demonstrate compliance with numerous accreditation standards spanning the areas of patient care, aviation, training/education, communications and safety. Christi Brewer, Air EMS Communication Supervisor stated, “We believe this accreditation speaks to our companies’ dedication to quality and safety. We look forward to growing the program while maintaining the highest standards.” About Air EMS. Air EMS is dedicated to providing safe, professional and timely patient care, transportation and medical support services to clients worldwide as a licensed provider of domestic and international air ambulance services. SDVOSB, VOSB, WOSB, HUBZone. To learn more about Air EMS, visit www.airems.us. About CAMTS.The CAMTS Mission Statement: “CAMTS is a peer review organization dedicated to improving patient care and transport safety by providing a dynamic accreditation process through the development of standards, education, and services that support our vision.” To learn more, visit www.camts.org. Tulsa, OK, February 25, 2017 --( PR.com )-- Air EMS, Inc. (Air EMS), a Service-Disabled Veteran-Owned Small Business (SDVOSB), proudly announced today that the company has been awarded conditional accreditation through the Commission on Accreditation of Medical Transport Systems (CAMTS) for its fixed-wing air ambulance and medical escort services.“Air EMS is honored to be accredited through CAMTS for medical escort and fixed-wing air ambulance transport at the Emergency Critical Care level. I could not be more proud of our team,” stated Air EMS President and Program Director, Angela Hall. Air EMS, in conjunction with its aviation operators, Jet Logistics and Flight Concepts, provide fixed-wing air ambulance transport to clients within the continental U.S. and worldwide utilizing a diverse fleet of aircraft including one of the industries only Hawker 800A’s for ultra long haul transports, in addition to Learjet 35/36 and others.CAMTS is an association of 21 non-profit organizations dedicated to improving the safety and quality of medical transport services through voluntary accreditation. To become accredited, a transport program must demonstrate compliance with numerous accreditation standards spanning the areas of patient care, aviation, training/education, communications and safety. Christi Brewer, Air EMS Communication Supervisor stated, “We believe this accreditation speaks to our companies’ dedication to quality and safety. We look forward to growing the program while maintaining the highest standards.”About Air EMS.Air EMS is dedicated to providing safe, professional and timely patient care, transportation and medical support services to clients worldwide as a licensed provider of domestic and international air ambulance services. SDVOSB, VOSB, WOSB, HUBZone. To learn more about Air EMS, visit www.airems.us.About CAMTS.The CAMTS Mission Statement: “CAMTS is a peer review organization dedicated to improving patient care and transport safety by providing a dynamic accreditation process through the development of standards, education, and services that support our vision.” To learn more, visit www.camts.org. Click here to view the list of recent Press Releases from Air EMS, Inc.
News Article | February 28, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Critical Care Therapeutics Market 2017-2021" report to their offering. The global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021. The report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. According to the report, one driver in market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. For instance, according to the CDC 2015 report, around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year. For more information about this report visit http://www.researchandmarkets.com/research/7k7m4d/global_critical